Shareholders Meeting Question: Does anyone know
Post# of 72440
Does anyone know what the limitations are for discussing or responding to questions about the status of trials, drugs, results, etc. at the shareholders meeting? Is it limited to the issues on the agenda or can those in attendance ask pointed questions about how certain trials are going or schedules/dates?
TIA